Shenzhen Chipscreen Biosciences Co (688321) - Total Liabilities
Based on the latest financial reports, Shenzhen Chipscreen Biosciences Co (688321) has total liabilities worth CN¥1.98 Billion CNY (≈ $289.34 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Shenzhen Chipscreen Biosciences Co (688321) equity growth momentum to track the company's year-over-year net asset growth rate.
Shenzhen Chipscreen Biosciences Co - Total Liabilities Trend (2016–2024)
This chart illustrates how Shenzhen Chipscreen Biosciences Co's total liabilities have evolved over time, based on quarterly financial data. See Shenzhen Chipscreen Biosciences Co free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Shenzhen Chipscreen Biosciences Co Competitors by Total Liabilities
The table below lists competitors of Shenzhen Chipscreen Biosciences Co ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bursa Malaysia Bhd
KLSE:1818
|
Malaysia | RM2.67 Billion |
|
Baoding Lucky Innovative Materials Co Ltd
SHE:300446
|
China | CN¥4.71 Billion |
|
Syngene International Limited
NSE:SYNGENE
|
India | Rs18.07 Billion |
|
Louis HachEtte Group SA
PA:ALHG
|
France | €9.64 Billion |
|
Hunan Nanling Industrial Explosive Materials Co Ltd
SHE:002096
|
China | CN¥3.87 Billion |
|
Bumitama Agri Ltd
F:2BU
|
Germany | €4.97 Trillion |
|
Zhewen Interactive Group Co Ltd
SHG:600986
|
China | CN¥4.32 Billion |
|
Zhejiang Medicine Co Ltd
SHG:600216
|
China | CN¥2.81 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Shenzhen Chipscreen Biosciences Co's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 688321 company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.54 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shenzhen Chipscreen Biosciences Co's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shenzhen Chipscreen Biosciences Co (2016–2024)
The table below shows the annual total liabilities of Shenzhen Chipscreen Biosciences Co from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.67 Billion ≈ $244.34 Million |
+11.82% |
| 2023-12-31 | CN¥1.49 Billion ≈ $218.52 Million |
+13.12% |
| 2022-12-31 | CN¥1.32 Billion ≈ $193.17 Million |
+176.87% |
| 2021-12-31 | CN¥476.79 Million ≈ $69.77 Million |
+105.12% |
| 2020-12-31 | CN¥232.44 Million ≈ $34.01 Million |
-5.16% |
| 2019-12-31 | CN¥245.10 Million ≈ $35.87 Million |
+2.36% |
| 2018-12-31 | CN¥239.44 Million ≈ $35.04 Million |
+16.53% |
| 2017-12-31 | CN¥205.47 Million ≈ $30.07 Million |
+8.30% |
| 2016-12-31 | CN¥189.73 Million ≈ $27.76 Million |
-- |
About Shenzhen Chipscreen Biosciences Co
Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research and development of original small molecule drugs. The company develops Chidamide, a subtype-selective histone deacetylase inhibitor for the treatment of peripheral T-cell lymphoma and advanced hormone receptor-positive breast cancer; Chiglitazar Sodium, a PPAR pan-agonist for the treatment of metabolic diseases; and Chiauranib, a t… Read more